Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Beta Drugs Ltd
Quarter-by-quarter operating performance
| Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 88.29 | 93.76 | 103.39 | 87.27 | 93.96 |
| Expenses + | 69.83 | 76.41 | 82.09 | 70.29 | 76.28 |
| Operating Profit | 18.46 | 17.35 | 21.30 | 16.98 | 17.68 |
| OPM % | 20.91% | 18.50% | 20.60% | 19.46% | 18.82% |
| Other Income + | -1.38 | 1.74 | 2.99 | 2.31 | 2.89 |
| Interest | 1.88 | 3.29 | 3.61 | 4.43 | 3.94 |
| Depreciation | 3.24 | 3.57 | 4.24 | 4.39 | 4.80 |
| Profit before tax | 11.96 | 12.23 | 16.44 | 10.47 | 11.83 |
| Tax % | 25.17% | 26.17% | 25.73% | 18.62% | 23.50% |
| Net Profit + | 8.95 | 9.03 | 12.22 | 8.52 | 9.05 |
| EPS in Rs | 8.86 | 8.95 | 12.11 | 8.40 | 8.93 |
Financials of Beta Drugs Ltd
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 |
| Expenses + | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | 24% |
| Net Profit + | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Beta Drugs Ltd
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 |
| Borrowings + | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 |
| Other Liabilities + | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
| Fixed Assets + | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets + | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 |
Financials of Beta Drugs Ltd
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Cash from Investing Activity + | -11 | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Cash from Financing Activity + | 5 | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| Net Cash Flow | 12 | -9 | 2 | 5 | 7 | 2 | 9 | 118 | -22 |
| Free Cash Flow | 9 | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
| CFO/OP | 181% | 1% | 47% | 75% | 69% | 44% | 52% | 48% | 49% |
Financials of Beta Drugs Ltd
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 | 113 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 | 97 |
| ROCE % | 18% | 21% | 22% | 36% | 34% | 33% | 27% | 19% |